JPWO2016098620A1 - 臓器構造体 - Google Patents
臓器構造体 Download PDFInfo
- Publication number
- JPWO2016098620A1 JPWO2016098620A1 JP2016564786A JP2016564786A JPWO2016098620A1 JP WO2016098620 A1 JPWO2016098620 A1 JP WO2016098620A1 JP 2016564786 A JP2016564786 A JP 2016564786A JP 2016564786 A JP2016564786 A JP 2016564786A JP WO2016098620 A1 JPWO2016098620 A1 JP WO2016098620A1
- Authority
- JP
- Japan
- Prior art keywords
- kidney
- bladder
- transplantation
- organ
- ureter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 110
- 210000003734 kidney Anatomy 0.000 claims abstract description 133
- 210000003932 urinary bladder Anatomy 0.000 claims abstract description 117
- 238000002054 transplantation Methods 0.000 claims abstract description 109
- 210000000626 ureter Anatomy 0.000 claims abstract description 80
- 241001465754 Metazoa Species 0.000 claims description 32
- 210000005260 human cell Anatomy 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 abstract description 50
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 26
- 241000282898 Sus scrofa Species 0.000 description 24
- 241000700159 Rattus Species 0.000 description 23
- 210000003754 fetus Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 210000000569 greater omentum Anatomy 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 210000005239 tubule Anatomy 0.000 description 11
- 241000282887 Suidae Species 0.000 description 9
- 230000003872 anastomosis Effects 0.000 description 9
- 230000036325 urinary excretion Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 206010020524 Hydronephrosis Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 230000029795 kidney development Effects 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002747 omentum Anatomy 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000003785 decidua Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002563 splenic artery Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000002620 ureteric effect Effects 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000024452 GDNF Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 1
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000000682 transitional epithelial cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3679—Hollow organs, e.g. bladder, esophagus, urether, uterus, intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/042—Urinary bladders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/048—Ureters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0091—Additional features; Implant or prostheses properties not otherwise provided for transparent or translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/26—Materials or treatment for tissue regeneration for kidney reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(1)腎臓と、尿管と、膀胱とを備える移植用臓器。
(2)移植対象とは異なる種の動物由来である、(1)に記載の移植用臓器。
(3)前記動物が遺伝子改変非ヒト動物である、(2)に記載の移植用臓器。
(4)前記動物がブタである、(2)又は(3)に記載の移植用臓器。
(5)実質的にヒト細胞からなる、(1)〜(4)のいずれかに記載の移植用臓器。
(6)ヒトへの移植用である、(1)〜(5)のいずれかに記載の移植用臓器。
(7)ネコへの移植用である、(1)〜(5)のいずれかに記載の移植用臓器。
(8)腎臓と、第1の尿管と、第1の膀胱と、第2の尿管と、第2の膀胱とが、この順に接続された臓器構造体。
(9)前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、前記第2の尿管及び前記第2の膀胱が由来する動物とは異なる種である、(8)に記載の臓器構造体。
(10)前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、遺伝子改変非ヒト動物である、(8)又は(9)に記載の臓器構造体。
(11)前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、ブタである、(8)〜(10)のいずれかに記載の臓器構造体。
(12)前記腎臓、前記第1の尿管及び前記第1の膀胱が、実質的にヒト細胞からなる、(8)〜(11)のいずれかに記載の臓器構造体。
(13)前記第2の尿管及び第2の膀胱が由来する動物が、ヒトである、(8)〜(12)のいずれかに記載の臓器構造体。
(14)前記第2の尿管及び第2の膀胱が由来する動物が、ネコである、(8)〜(12)のいずれかに記載の臓器構造体。
1実施形態において、本発明は、腎臓と、尿管と、膀胱とを備える移植用臓器を提供する。なお、本明細書において、用語「腎臓」は、後腎等の腎臓原器を含むものとする。また、用語「膀胱」は、尿排泄腔等の膀胱原器を含むものとする。
1実施形態において、本発明は、腎臓と、第1の尿管と、第1の膀胱と、第2の尿管と、第2の膀胱とが、この順に接続された臓器構造体を提供する。
1実施形態において、本発明は、腎臓、尿管及び膀胱を備える移植用臓器を患者又は患畜の体内に移植する工程(a)と、移植から所定期間後に上記移植用臓器の膀胱と、患者又は患畜の尿管とを接続する工程(b)と、を備える、腎臓の移植方法を提供する。患者又は患畜としては、例えば、ヒト、ネコが挙げられる。
(ブタへの腎臓移植及び移植腎臓の解析)
体細胞クローン技術を用いてクローンブタを作製した。続いて、胎生30日目のクローンブタの胎仔を摘出し、顕微鏡下でブタ後腎(以下「MN(metanephroi)」という場合がある。)を摘出した。図2Aは、胎生30日目のクローンブタの胎仔の写真である。図2Bは、摘出したブタ後腎の写真である。続いて、シンジェニックなブタの大網に、摘出した後腎を移植した。図2Cは移植の様子を示す写真である。後腎の大網への移植から3週間後、5週間後及び8週間後に、ブタをイソフルラン麻酔下でと殺し、移植した後腎を摘出して解析した。
(ラットへの腎臓移植及び移植腎臓の解析)
図4A及び図4Bは、実験概要を説明する図である。腎臓を移植するホストラットとしては、10週齢のルイスラット(三協ラボサービス社又は日本クレア社)を用いた。
(ラットの尿排泄路の構築)
胎生15日目のラット胎仔から、膀胱付き後腎、すなわち、腎臓、尿管及び膀胱を備えた臓器(CL)を摘出し、ラットの傍大動脈領域に移植した。続いて、移植4週間後にホストラットの左腎を摘出し、移植した後腎の膀胱(CL膀胱)とホストラットの左尿管を顕微鏡下に吻合する手術を行った。
(ブタへの膀胱付き腎臓移植及び移植腎臓の解析)
胎生30日目のブタ胎仔から、膀胱付き後腎、すなわち、腎臓、尿管及び膀胱を備えた臓器(CL)を摘出し、シンジェニックなブタの大網に移植した。図12Aに示すように、移植された膀胱付き後腎はラットの実験同様に順調に発育し、移植後3週間で尿を産生した。また、図12Bに示すように、移植後5週間で更に巨大化した。CL膀胱内に蓄積した尿は、尿素窒素及びクレアチニンが濃縮されていることが確認された。
(ブタの尿排泄路の構築)
クローンブタを用いてSPWU systemによる尿排泄路の構築を行った。胎生30日目のブタ胎仔から、膀胱付き後腎、すなわち、腎臓、尿管及び膀胱を備えた臓器(CL)を摘出し、シンジェニックなブタの傍大動脈及び脾動脈周辺に移植した。
Claims (14)
- 腎臓と、尿管と、膀胱とを備える移植用臓器。
- 移植対象とは異なる種の動物由来である、請求項1に記載の移植用臓器。
- 前記動物が遺伝子改変非ヒト動物である、請求項2に記載の移植用臓器。
- 前記動物がブタである、請求項2又は3に記載の移植用臓器。
- 実質的にヒト細胞からなる、請求項1〜4のいずれか一項に記載の移植用臓器。
- ヒトへの移植用である、請求項1〜5のいずれか一項に記載の移植用臓器。
- ネコへの移植用である、請求項1〜5のいずれか一項に記載の移植用臓器。
- 腎臓と、第1の尿管と、第1の膀胱と、第2の尿管と、第2の膀胱とが、この順に接続された臓器構造体。
- 前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、前記第2の尿管及び前記第2の膀胱が由来する動物とは異なる種である、請求項8に記載の臓器構造体。
- 前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、遺伝子改変非ヒト動物である、請求項8又は9に記載の臓器構造体。
- 前記腎臓、前記第1の尿管及び前記第1の膀胱が由来する動物が、ブタである、請求項8〜10のいずれか一項に記載の臓器構造体。
- 前記腎臓、前記第1の尿管及び前記第1の膀胱が、実質的にヒト細胞からなる、請求項8〜11のいずれか一項に記載の臓器構造体。
- 前記第2の尿管及び第2の膀胱が由来する動物が、ヒトである、請求項8〜12のいずれか一項に記載の臓器構造体。
- 前記第2の尿管及び第2の膀胱が由来する動物が、ネコである、請求項8〜12のいずれか一項に記載の臓器構造体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014257957 | 2014-12-19 | ||
JP2014257957 | 2014-12-19 | ||
PCT/JP2015/084216 WO2016098620A1 (ja) | 2014-12-19 | 2015-12-04 | 移植用臓器及び臓器構造体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016098620A1 true JPWO2016098620A1 (ja) | 2017-07-27 |
JP6220991B2 JP6220991B2 (ja) | 2017-10-25 |
Family
ID=56126513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016564786A Active JP6220991B2 (ja) | 2014-12-19 | 2015-12-04 | 移植材料 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10335263B2 (ja) |
EP (1) | EP3222298A4 (ja) |
JP (1) | JP6220991B2 (ja) |
KR (2) | KR20190057439A (ja) |
CN (3) | CN117085181A (ja) |
WO (1) | WO2016098620A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11559605B2 (en) * | 2016-06-29 | 2023-01-24 | Takashi Yokoo | Kidney production method |
WO2018003450A1 (ja) * | 2016-06-29 | 2018-01-04 | 隆 横尾 | 臓器の製造方法 |
EP3480298A4 (en) * | 2016-06-29 | 2020-01-22 | Takashi Yokoo | RENAL PROCESS |
WO2022250147A1 (ja) * | 2021-05-28 | 2022-12-01 | 学校法人慈恵大学 | 移植材料及び腎移植キット |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511501A (ja) * | 2001-09-07 | 2005-04-28 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 発達中の腎臓組織を使用した腎臓移植方法 |
WO2006117889A1 (ja) * | 2005-04-28 | 2006-11-09 | Stemcell Institute Inc. | 移植用臓器の調製方法 |
WO2010001951A1 (ja) * | 2008-07-02 | 2010-01-07 | 株式会社大塚製薬工場 | 人工腎臓前駆体およびその製造方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228550A (en) * | 1979-06-29 | 1980-10-21 | Henry Salkind | Distal urinary replacement prosthesis |
US6613095B1 (en) * | 2000-10-20 | 2003-09-02 | John M. Levin | Prosthesis for continuous internal peritoneal dialysis and continuous method of providing peritoneal dialysis |
CN2524711Y (zh) * | 2001-09-28 | 2002-12-11 | 靳凤烁 | 智能型原位植入式人工膀胱 |
GB0218916D0 (en) * | 2002-08-14 | 2002-09-25 | Plc | Kidney foundation |
ATE531419T1 (de) * | 2003-12-15 | 2011-11-15 | Nitricare Hb | Vorrichtung zur verabreichung von therapeutischen mitteln |
US20070023910A1 (en) * | 2005-07-29 | 2007-02-01 | Texas Instruments Incorporated | Dual BGA alloy structure for improved board-level reliability performance |
DE102006009539A1 (de) | 2006-02-28 | 2007-09-06 | Technische Universität Dresden | Prävaskularisierte Gewebetransplantatkonstrukte zur Rekonstruktion eines menschlichen oder tierischen Organs |
EP2014316A4 (en) * | 2006-04-24 | 2010-07-28 | Stemcell Inst Inc | PROCESS FOR PREPARING AN ORGAN FOR TRANSPLANTATION |
WO2012122267A1 (en) * | 2011-03-07 | 2012-09-13 | Theranova, Llc | Sensing foley catheter |
US8511838B2 (en) * | 2011-06-29 | 2013-08-20 | Microvision, Inc. | Scanning laser projector with safety system |
-
2015
- 2015-12-04 US US15/535,682 patent/US10335263B2/en active Active
- 2015-12-04 EP EP15869825.8A patent/EP3222298A4/en active Pending
- 2015-12-04 CN CN202311038477.4A patent/CN117085181A/zh active Pending
- 2015-12-04 KR KR1020197014369A patent/KR20190057439A/ko active Application Filing
- 2015-12-04 WO PCT/JP2015/084216 patent/WO2016098620A1/ja active Application Filing
- 2015-12-04 JP JP2016564786A patent/JP6220991B2/ja active Active
- 2015-12-04 KR KR1020177016740A patent/KR102186330B1/ko active IP Right Grant
- 2015-12-04 CN CN201580068092.XA patent/CN107106728A/zh active Pending
- 2015-12-04 CN CN202410221162.1A patent/CN118078492A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511501A (ja) * | 2001-09-07 | 2005-04-28 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 発達中の腎臓組織を使用した腎臓移植方法 |
WO2006117889A1 (ja) * | 2005-04-28 | 2006-11-09 | Stemcell Institute Inc. | 移植用臓器の調製方法 |
WO2010001951A1 (ja) * | 2008-07-02 | 2010-01-07 | 株式会社大塚製薬工場 | 人工腎臓前駆体およびその製造方法 |
Non-Patent Citations (4)
Title |
---|
TORINO, G. ET AL.: "Combined Kidney and Vascularized Total Bladder Transplantation: Experience in an Animal Model", TRANSPLANTATION PROCEEDINGS, vol. 45, JPN6016005468, 2013, pages 2765 - 2768, XP055455357, ISSN: 0003632308, DOI: 10.1016/j.transproceed.2013.07.047 * |
増田正孝ら: "同種腎臓移植の実験的研究 特に仔犬腎臓移植片の抗原性について", 日本人工臓器学会雑誌, vol. 3, no. 1, JPN6016005469, 1966, pages 32 - 33, ISSN: 0003632309 * |
小林英司ら: "ブタを利用してヒトの腎臓をつくる", 今日の移植, vol. 25, no. 4, JPN6016005470, 2012, pages 355 - 358, ISSN: 0003632310 * |
横尾隆: "臨床応用に向けた腎臓再生研究−第58回日本透析医学会教育講演より−", 透析会誌, vol. 46, no. 11, JPN6016005471, 2013, pages 1055 - 1060, ISSN: 0003632311 * |
Also Published As
Publication number | Publication date |
---|---|
US20170333173A1 (en) | 2017-11-23 |
KR20190057439A (ko) | 2019-05-28 |
EP3222298A1 (en) | 2017-09-27 |
KR102186330B1 (ko) | 2020-12-03 |
EP3222298A4 (en) | 2018-10-17 |
JP6220991B2 (ja) | 2017-10-25 |
CN117085181A (zh) | 2023-11-21 |
WO2016098620A1 (ja) | 2016-06-23 |
KR20170097659A (ko) | 2017-08-28 |
CN107106728A (zh) | 2017-08-29 |
US10335263B2 (en) | 2019-07-02 |
CN118078492A (zh) | 2024-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4814226B2 (ja) | 移植用臓器の調製方法 | |
JP6220991B2 (ja) | 移植材料 | |
JP7488177B2 (ja) | 腎臓の製造方法 | |
US20220288127A1 (en) | Lymph node as a site for transplantation, organogenesis and function for multiple tissues and organs | |
JP2021045168A (ja) | 腎臓の製造方法 | |
US20090186004A1 (en) | Method For Preparing An Organ For Transplantation | |
WO2018228534A1 (zh) | 制备免疫缺陷的大鼠的方法及其应用 | |
JPWO2008004598A1 (ja) | エリスロポエチン産出オルガノイド前駆体及びその製造方法並びにエリスロポエチン関連疾患の治療方法 | |
WO2018003450A1 (ja) | 臓器の製造方法 | |
JP2021069432A (ja) | 移植材料及びステント | |
Morimoto et al. | Fetal Kidney Transplantation for In Utero Fetuses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170428 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20170428 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20170524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170808 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171002 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6220991 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |